019 Four Drugs, One Goal - A New Option for Older Myeloma Patients

Welcome to The Myeloma Minutes. We've now moved to a fortnightly release schedule, so you can now hear us every-other Thursday.

This episode explains the newly approved four-drug treatment (Isatuximab, Velcade, Lenalidomide and Dexamethasone) for older people with myeloma who are not eligible for a stem cell transplant.

📌Key Takeaways:

• This four-drug ‘quadruplet’ can keep myeloma under control for many years — even in older patients.
• Each drug works differently, combining to give stronger and longer remissions.
• Side effects like infection, neuropathy or diarrhoea are real — but doses can be tailored to keep patients well.

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.